Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protocadherin beta-5 (PCDHB5) is a neural cadherin-like cell adhesion protein belonging to the protocadherin beta gene cluster on chromosome 5. It is part of the cadherin superfamily and distinguished by encoding six extracellular cadherin domains and a cytoplasmic tail that diverges from other cadherin types. These proteins are thought to mediate homophilic, calcium-dependent cell-cell adhesion, primarily in the nervous system, and are likely important for the establishment and function of specific neuronal circuits. While the specific functional and mechanistic details for protocadherin beta-5 remain incompletely understood, gene expression studies implicate its upregulation in aggressive forms of retinoblastoma, suggesting a possible role as a cancer biomarker. To date, PCDHB5 is not a known or established therapeutic target, and there are no drugs reported to interact directly with it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protocadherin beta-5 (PCDHB5).